BC
MTNB icon

Broadfin Capital’s Matinas BioPharma MTNB Stock Holding History

Broadfin Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,334
Closed -$657K – 47
2019
Q2 		$657K Sell
15,334
-39,211
-72% -$1.88M 0.14% 39
2019
Q1 		$2.97M Buy
+54,545
New +$2.94M 0.61% 37

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Broadfin Capital's MTNB Position: Q3 2019 in Review

Broadfin Capital sold out of Matinas BioPharma (MTNB) in Q3 2019, closing a stake of 15,334 shares — an estimated $657K sold.

Broadfin Capital first reported a position in MTNB in Q1 2019 and held it in 2 quarters. The position peaked at $2.97M in Q1 2019. 37 funds tracked by Wall St. Rank hold MTNB as of Q3 2019.

  • Broadfin Capital reported no remaining Matinas BioPharma position as of Q3 2019 after selling out during the quarter.
  • Broadfin Capital sold 15,334 Matinas BioPharma shares in Q3 2019, an estimated $657K.
  • Broadfin Capital first reported a position in Matinas BioPharma in Q1 2019 and held it in 2 quarters.
  • Broadfin Capital's Matinas BioPharma position peaked at $2.97M in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2019.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.